Table 2 Initial treatment of men diagnosed with T1/T2 cancer

From: Clinical presentation and initial management of Black men and White men with prostate cancer in the United Kingdom: the PROCESS cohort study

   

Adjusted for

  
 

Black men

White men

Centre ( n =947)

Centre and age ( n =947)

Centre, age, grade, stage, and comorbidity ( n =846)

 

n (%)

n (%)

OR (95% CI)

P -value

OR (95% CI)

P -value

OR (95% CI)

P -value

Has T1/T2 cancer

332

663

      

 and initial treatment recorded

314 (95)

633 (95)

      

No treatment

50 (16)

188 (30)

      

Hormone therapy

118 (38)

249 (39)

      

Curative radiotherapy

104 (33)

123 (19)

1.67 (1.20, 2.32)

0.002

0.85 (0.58, 1.23)

0.39

0.77 (0.51, 1.14)

0.19

Curative surgery

42 (13)

73 (12)

1.44 (0.92, 2.27)

0.114

0.67 (0.38, 1.16)

0.15

0.79 (0.42, 1.48)

0.45

Curative radiotherapy or surgery

146 (46)

196 (31)

1.57 (1.17, 2.10)

0.003

0.74 (0.52, 1.05)

0.088

0.71 (0.49, 1.03)

0.074

  1. Abbreviations: CI, confidence interval; OR=odds ratio.
  2. Comparisons are against the combination of no treatment+hormone therapy. Dummy covariates distinguish the five centres, three age groups (44–68, 69–76, and 77–94 years), three groups of Gleason scores (⩽6, 7, and 8+), two stages (T1 and T2), and three groups of Charlson scores (0, 1, and 2+).
Back to article page